Browse drugs

… therapeutic positioning.Aim and Objectives To evaluate whether pembrolizumab, dostarlimab, durvalumab, durvalumab plus olaparib, and atezoli…

…p Chemiluminescent Microparticle Immunoassay (Abbott Architect).Insulin and C-peptide were measured in serum using a Roche Cobas 6000 a…

…)0.73 Diuretic 5 (17%)6 (19%)>0.99 Statin 23 (77%)25 (78%)>0.99 Biguanide 20 (67%)26 (81%)0.25 Sulphonylurea 1 (3%)1 (3%)>0.99 GLP1-RA 1 …

…arm, 7.5% in the atezolizumab+bevacizumab arm, and 15.4% in the docetaxel (control) arm. There were no clear correlations of response or …

…. There were no severe and serious ARs in DIV group.Conclusions Divozilimab treatment leads to significant decrease of skin fibrosis compar…

…son to placebo finds no difference in terms of incidence of RP. Ketamine, a non-selective inhibitor of N-methyl-D-aspartate receptors th…

…ease, chronic kidney disease, non-liver cancer, CCI, metformin, DPP-4i, CLP-1RA, sulfonylureas, thiazolidinediones, insulin, ACEI/ARB,…

… sensitivity, but lower specificity than adenosine-stress CMRD. Dobutamine- and adenosine-stress CMR showed comparable sensitivity, specif…

…UDCA), obeticholic acid (OCA), and amongst those switching from bezafibrate (BZF).Results From Dec 2024 to Nov 2025, 54 pts initiated Ela (…

…: p=0,0482; Anti-IL12/23 vs Anti-TNF: p=0,0480; Risankizumab vs Ustekinumab: p=0,0116. No significant differences were found between Risank…

…9% male; 64.6% received fremanezumab, 24.8% erenumab, 10.6% and galcanezumab; 75.7% were on first-line therapy, 21.7% second-line and 2.7% t…

…s Affairs users with type 2 diabetes who started treatment with GLP-1RAs (n=132 551) or sulfonylureas (n=201 136), followed up for three…